Experimental cancer drug THOR-707 trial halted early
Disease control
Terminated
This study tested an experimental drug called THOR-707, alone or with other treatments, in adults with advanced or metastatic solid tumors. The main goals were to find safe doses and see if the drug could shrink tumors. The trial was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Synthorx, Inc, a Sanofi company • Aim: Disease control
Last updated May 13, 2026 16:00 UTC